Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Axcella Health Inc. | tm2020068d1_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - Axcella Health Inc. | tm2020068d1_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 18, 2020
AXCELLA HEALTH INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38901 | 26-3321056 | ||||||||||||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||||||||||||
| 840 Memorial Drive Cambridge, Massachusetts |
02139 | ||||
| (Address of principal executive offices) | (Zip Code) | ||||
Registrant's telephone number, including area code: (857) 320-2200
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, $0.001 Par Value | AXLA | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
On May 13, 2020, Axcella Health Inc. (the “Company”) announced the pricing of its public offering of common stock. On May 18, 2020, the Company announced the closing of its public offering of common stock, including the full exercise of the underwriters’ option to purchase additional shares. Copies of the press releases are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2 and are incorporated by reference herein.
| Item 9.01. | Financial Statements and Exhibits. | |
(d) Exhibits:
| Exhibit No. |
Description | |||||||
| 99.1 | Press release issued by Axcella Health Inc., dated May 13, 2020 | |||||||
| 99.2 | Press release issued by Axcella Health Inc., dated May 18, 2020 | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AXCELLA HEALTH INC. | ||
| Date: May 18, 2020 | By: / | s/ William R. Hinshaw, Jr. |
| William R. Hinshaw, Jr. | ||
| Chief Executive Officer, President and Director | ||